Purpose: To determine whether whole-body total lesion glycolysis (TLG), which combines volumetric and metabolic information from fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT), can provide a better evaluation of the prognosis for non-small cell lung cancer (NSCLC).
Materials And Methods: The institutional review board approved this retrospective study, and the requirement to obtain informed consent was waived. The authors identified 105 consecutive patients with NSCLC who underwent staging FDG PET/CT before any therapy. These patients were free of brain metastasis and underwent standard treatment and subsequent clinical follow-up. Metabolic tumor volume (MTV), mean standardized uptake value (SUV), and maximum SUV of each tumor over the whole body were determined. Whole-body MTV and whole-body TLG are the summation of all the MTVs and summation of individual tumor volume multiplied by its mean SUV, respectively. Univariate and multivariate analyses were performed to assess the prognostic significance of whole-body TLG and other factors, including whole-body MTV, lung TLG, lung MTV, maximum SUV, sex, age, performance status, histologic subtype, T stage, N stage, clinical stage, and treatment method.
Results: The median follow-up time was 3.1 years. The estimated median progression-free survival (PFS) and overall survival (OS) for the cohort was 10.8 months and 2.8 years, respectively. The 1-year PFS was 0.0% for patients with high whole-body TLG (>655) and 50.0% for those with low whole-body TLG (≤655). The 1-year OS was 58.8% for patients with high whole-body TLG and 84.1% for those with low whole-body TLG. Univariate analysis showed that whole-body TLG, whole-body MTV, lung TLG, lung MTV, maximum SUV, performance status, T stage, N stage, clinical stage, and treatment type (surgery vs other) were significant prognostic factors for PFS (P < .01 for all). With use of the forward stepwise multivariate Cox proportional hazards model, whole-body TLG (hazard ratio = 2.92; 95% confidence interval: 1.62, 5.26; P < .01) and surgical treatment (hazard ratio = 4.24; 95% confidence interval: 2.54, 7.07; P < .01) remained significant in PFS.
Conclusion: Whole-body TLG is of prognostic value for NSCLC. It may be a promising tool for stratifying patients with NSCLC for risk-adapted therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1148/radiol.12111148 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The value of a nomogram based on 18F-FDG PET/CT metabolic parameters and metabolic heterogeneity in predicting distant metastasis in gastric cancer.
Jpn J Clin Oncol
December 2024
Department of Nuclear Medicine, Second Affiliated Hospital of Fujian Medical University, Donghai Street No. 950, Fengze District, Quanzhou 362018, PR China.
Objective: To investigate the value of metabolic parameters and metabolic heterogeneity from pretreatment deoxy-2-[fluorine-18]-fluoro-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in predicting distant metastasis in gastric cancer.
Methods: Eighty-six patients with pathologically confirmed gastric adenocarcinoma were included in this study. All patients underwent a whole-body 18F-FDG PET/CT scan before treatment.
Analysis of Molecular Imaging Biomarkers Derived from [F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [Ac]Ac-PSMA-617-Augmented [Lu]Lu-PSMA-617 Radioligand Therapy.
Cancers (Basel)
October 2024
Department of Nuclear Medicine, Saarland University Medical Center, 66421 Homburg, Germany.
The augmentation of [Lu]Lu-PSMA-617 radioligand therapy by alpha emitting [Ac]Ac-PSMA-617, known as the tandem therapy concept, is a promising escalating treatment option in advanced mCRPC. In this study, we evaluated the value of [F]FDG PET/CT-derived molecular imaging biomarkers for predicting response and outcome to PSMA tandem RLT in = 33 patients with insufficient response on [Lu]Lu-PSMA-617 monotherapy. Six different molecular imaging parameters at baseline, i.
View Article and Find Full Text PDFPrognostic Importance of F-FDG Positron Emission Tomography in Uterine Cervical Cancer.
Mol Imaging Radionucl Ther
October 2024
Ankara University Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara, Türkiye.
Article Synopsis
- The study aimed to assess how well F-FDG PET/CT imaging can predict outcomes in patients with uterine cervix cancer by looking at various metabolic parameters.
- A total of 32 women were analyzed, showing that a significant percentage had active primary tumors, with specific metrics like SUV and TLG correlating with disease progression and overall survival.
- The findings indicate that certain PET parameters, especially those related to the primary tumors, could serve as important prognostic indicators for patient outcomes.
The prognostic role of whole-body volumetric positron emission tomography/computed tomography parameters in treatment naive colorectal cancer patients with liver metastases.
Nucl Med Commun
January 2025
Department of Nuclear Medicine, Saglik Bilimleri University Diyarbakir Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey.
Purpose: The present study aimed to predict the prognostic role of quantitative 18 F-fluorodeoxyglucose PET/computed tomography parameters such as maximum standardized uptake value (SUV max ), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) obtained from primary tumor, lymph node metastases, and liver metastasis (LM) in patients with colorectal LM (CLM).
Material And Method: The research was designed as a retrospective study and 66 patients with CLM were enrolled between January 2017 and December 2018. Primary tumor SUV max (PSUV max ), liver SUV max (LSUV max ), and lymph node SUV max (LnSUV max ) values obtained from the primary tumor, liver, and lymph nodes were recorded.
Incorporation of whole-body metabolic tumor burden into current prognostic models for nonsmall cell lung cancer patients with spine metastasis.
Spine J
February 2025
Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Medical Device Development, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address:
Background Context: Numerous prognostic models are utilized for surgical decision and prognostication in metastatic spine tumors. However, these models often fail to consider the whole-body tumor burden into account, which may be crucial for the prognosis of metastatic cancers. A potential surrogate marker for tumor burden, whole-body metabolic tumor burden (wMTB), can be calculated from total lesion glycolysis (TLG) obtained from F-Fludeoxyglucose positive emission tomography (F-FDG PET) images.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!